Literature DB >> 16901375

Countermeasures for sleep loss and deprivation.

Clete A Kushida1.   

Abstract

Sleep deprivation is ubiquitous and carries profound consequences in terms of personal and public health and safety. There is no substitute for a good night's sleep. Sleep that is optimal in quality and quantity for individuals, factoring in their age and personal sleep requirements, will minimize sleep debt and maximize daytime performance. Therefore, setting aside an adequate amount of time for sleep should be a priority; sleep should not be sacrificed at the expense of other activities of daily living. Nevertheless, there are certain therapeutic countermeasures available for individuals who are unable to obtain adequate sleep because of medical or sleep-related conditions (eg, narcolepsy, obstructive sleep apnea) when excessive daytime sleepiness is the main feature of the condition, or residual sleepiness despite treatment for the main conditions is present. These therapeutic countermeasures may also be considered in situations in which occupational constraints (eg, rotating shift work, military duty) dictate that constant or heightened vigilance is important or critical to work performance, crucial decision making, and/or survival. Exploration of the causes of sleep loss or deprivation, whether it is voluntary, or work or family induced, and/or the effects of a medical or sleep disorder, is a necessary first step in the evaluation of a patient who has significant daytime fatigue or sleepiness. Wake-promoting substances and medications such as caffeine, modafinil, methylphenidate, and dextroamphetamine may be considered in situations in which sleep loss is unavoidable or persists despite treatment of an underlying disorder that is characterized by or associated with daytime fatigue or sleepiness.

Entities:  

Year:  2006        PMID: 16901375     DOI: 10.1007/s11940-006-0025-7

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  4 in total

1.  Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work.

Authors:  Paula K Schweitzer; Angela C Randazzo; Kara Stone; Milton Erman; James K Walsh
Journal:  Sleep       Date:  2006-01       Impact factor: 5.849

Review 2.  We are chronically sleep deprived.

Authors:  M H Bonnet; D L Arand
Journal:  Sleep       Date:  1995-12       Impact factor: 5.849

3.  Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature.

Authors: 
Journal:  J Sleep Res       Date:  1995-12       Impact factor: 3.981

4.  Sleepiness as measured by modified multiple sleep latency testing varies as a function of preceding activity.

Authors:  M H Bonnet; D L Arand
Journal:  Sleep       Date:  1998-08-01       Impact factor: 5.849

  4 in total
  4 in total

1.  Wake-promoting agent modafinil worsened attentional performance following REM sleep deprivation in a young-adult rat model of 5-choice serial reaction time task.

Authors:  Yia-Ping Liu; Che-Se Tung; Yu-Lung Lin; Chia-Hsin Chuang
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

2.  The separate and combined effects of hypoxia and sustained recumbency/inactivity on sleep architecture.

Authors:  Bojan Rojc; Shawnda A Morrison; Ola Eiken; Igor B Mekjavic; Leja Dolenc-Grošelj
Journal:  Eur J Appl Physiol       Date:  2014-06-12       Impact factor: 3.078

3.  Daytime Sleepiness, Circadian Preference, Caffeine Consumption and Use of Other Stimulants among Thai College Students.

Authors:  Jason Tran; Somrat Lertmaharit; Vitool Lohsoonthorn; Wipawan C Pensuksan; Thanapoom Rattananupong; Mahlet G Tadesse; Bizu Gelaye; Michelle A Williams
Journal:  J Public Health Epidemiol       Date:  2014-06

Review 4.  A review of sleep deprivation studies evaluating the brain transcriptome.

Authors:  Alisa S Elliott; Jason D Huber; James P O'Callaghan; Charles L Rosen; Diane B Miller
Journal:  Springerplus       Date:  2014-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.